

Gianmaria Miolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/40404/publications.pdf>

Version: 2024-02-01

58
papers

800
citations

567281
15
h-index

552781
26
g-index

59
all docs

59
docs citations

59
times ranked

1715
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer. <i>Oncotarget</i> , 2016, 7, 39809-39822.	1.8	72
2	Clinical validity of a <sc><i>DPYD</i></sc>-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. <i>International Journal of Cancer</i> , 2015, 137, 2971-2980.	5.1	70
3	Autosomal Dominant Pseudohypoparathyroidism Type Ib: A Novel Inherited Deletion Ablating<i>STX16</i> Causes Loss of Imprinting at the A/B DMR. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E724-E728.	3.6	68
4	Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. <i>Journal of Translational Medicine</i> , 2015, 13, 204.	4.4	64
5	Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 791-797.	2.8	50
6	Metabolomics Biomarkers of Frailty in Elderly Breast Cancer Patients. <i>Journal of Cellular Physiology</i> , 2014, 229, 898-902.	4.1	40
7	Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 918-924.	7.0	35
8	A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. <i>Breast Cancer Research</i> , 2011, 13, R117.	5.0	30
9	Use of Metabolomics as a Complementary Omic Approach to Implement Risk Criteria for First-Degree Relatives of Gastric Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2018, 19, 750.	4.1	26
10	Carcinogenesis and Metastasis in Liver: Cell Physiological Basis. <i>Cancers</i> , 2019, 11, 1731.	3.7	26
11	Malignant cardiac tumors: diagnosis and treatment. <i>Future Cardiology</i> , 2015, 11, 485-500.	1.2	25
12	Effect of Estrogen Receptor Status on Circulatory Immune and Metabolomics Profiles of HER2-Positive Breast Cancer Patients Enrolled for Neoadjuvant Targeted Chemotherapy. <i>Cancers</i> , 2020, 12, 314.	3.7	22
13	Polymorphism in Toll-Like Receptors and Helicobacter Pylori Motility in Autoimmune Atrophic Gastritis and Gastric Cancer. <i>Cancers</i> , 2019, 11, 648.	3.7	20
14	Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype. <i>International Journal of Molecular Sciences</i> , 2018, 19, 47.	4.1	17
15	Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy. <i>BMC Medical Genetics</i> , 2016, 17, 11.	2.1	16
16	Quantitative Proteomic Approach Targeted to Fibrinogen β^2 Chain in Tissue Gastric Carcinoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 759.	4.1	16
17	Therapeutic management of breast cancer in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 945-960.	1.8	15
18	Integration of Serum Metabolomics into Clinical Assessment to Improve Outcome Prediction of Metastatic Soft Tissue Sarcoma Patients Treated with Trabectedin. <i>Cancers</i> , 2020, 12, 1983.	3.7	15

#	ARTICLE	IF	CITATIONS
19	Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy. BMC Cancer, 2006, 6, 156.	2.6	13
20	Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer. Cancers, 2019, 11, 880.	3.7	11
21	Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients. BMC Cancer, 2014, 14, 954.	2.6	9
22	Morphologic shift associated with aberrant cytokeratin expression in a GIST patient after tyrosine kinase inhibitors therapy. A case report with a brief review of the literature. Pathology Research and Practice, 2016, 212, 63-67.	2.3	9
23	Primary extragenital endometrial stromal sarcoma of the lung: first reported case and review of literature. Diagnostic Pathology, 2017, 12, 36.	2.0	9
24	A new mutation of the CDH1 gene in a patient with an aggressive signet-ring cell carcinoma of the stomach. Cancer Biology and Therapy, 2018, 19, 254-259.	3.4	9
25	Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study. BMC Cancer, 2010, 10, 205.	2.6	8
26	Mesenchymal chondrosarcoma of the spleen: Report of a case. Tumori, 2011, 97, e10-e15.	1.1	7
27	Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications. Cancer Biology and Therapy, 2014, 15, 1439-1443.	3.4	7
28	Target therapy in elderly breast cancer patients. Critical Reviews in Oncology/Hematology, 2012, 83, 422-431.	4.4	6
29	Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients. International Journal of Clinical Oncology, 2013, 18, 510-516.	2.2	6
30	From Metabolism to Genetics and Vice Versa: The Rising Role of Oncometabolites in Cancer Development and Therapy. International Journal of Molecular Sciences, 2021, 22, 5574.	4.1	6
31	¹ H-NMR Plasma Lipoproteins Profile Analysis Reveals Lipid Metabolism Alterations in HER2-Positive Breast Cancer Patients. Cancers, 2021, 13, 5845.	3.7	6
32	Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST. International Journal of Colorectal Disease, 2014, 29, 639-640.	2.2	5
33	The metabolomic scent of cancer disease progression in soft tissue sarcoma: A case report. International Journal of Biological Markers, 2019, 34, 205-209.	1.8	5
34	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. Cancers, 2021, 13, 3504.	3.7	5
35	Systemic Treatments for Advanced Small Bowel Adenocarcinoma: A Systematic Review. Cancers, 2022, 14, 1502.	3.7	5
36	Lapatinib-Based Therapy in Heavily Pretreated HER2-Positive Metastatic Breast Cancer: A Single Institution Experience. Tumori, 2012, 98, 33-38.	1.1	4

#	ARTICLE	IF	CITATIONS
37	A novel mosaic 1q32.1 microduplication identified through Chromosome Microarray Analysis: narrowing the smallest critical region including KDM5B gene found associated with neurodevelopmental disorders. <i>European Journal of Medical Genetics</i> , 2019, 62, 103558.	1.3	4
38	Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience. <i>Tumori</i> , 2014, 100, 605-11.	1.1	4
39	Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience. <i>Tumori</i> , 2012, 98, 33-8.	1.1	4
40	Incidence of Palmar-Plantar Erythrodysesthesia in Pretreated and Unpretreated Patients Receiving Pegylated Liposomal Doxorubicin. <i>Tumori</i> , 2009, 95, 687-690.	1.1	3
41	Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers. <i>BMC Cancer</i> , 2009, 9, 360.	2.6	3
42	Epirubicin and Docetaxel as Neoadjuvant Treatment of Locally Advanced Breast Cancer: A Phase II Study. <i>Tumori</i> , 2010, 96, 229-233.	1.1	3
43	Chemo/Tomotherapy Stereotactic Body Radiation Therapy (chemo/SBRT) for the Salvage Treatment of Esophageal Carcinoma following Trimodality Therapy: A Case Report. <i>Tumori</i> , 2012, 98, e143-e145.	1.1	3
44	Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma. <i>Cancer Biology and Therapy</i> , 2016, 17, 1017-1021.	3.4	3
45	Heterozygous variant at nucleotide position 875+11A>T in exon 6A cystic fibrosis transmembrane conductance regulator gene induces 852del22 mutation false-positivity by line probe assay. <i>Fertility and Sterility</i> , 2011, 95, 1121.e1-1121.e4.	1.0	2
46	Rapid LC-MS/MS method for quantification of vinorelbine and 4'-deacetylvinorelbine in human whole blood suitable to monitoring oral metronomic anticancer therapy. <i>Biomedical Chromatography</i> , 2018, 32, e4282.	1.7	2
47	Cancer survivors: surveillance or not surveillance?. <i>Annals of Oncology</i> , 2019, 30, 1531.	1.2	2
48	Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin. <i>Tumori</i> , 2009, 95, 687-90.	1.1	2
49	KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 791958.	4.8	2
50	HER2-CDH1 Interaction via Wnt/B-Catenin Is Associated with Patients' Survival in HER2-Positive Metastatic Gastric Adenocarcinoma. <i>Cancers</i> , 2022, 14, 1266.	3.7	2
51	Chemo/tomotherapy stereotactic body radiation therapy (chemo/SBRT) for the salvage treatment of esophageal carcinoma following trimodality therapy: a case report. <i>Tumori</i> , 2012, 98, 143e-145e.	1.1	2
52	Comment on "Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: Local control and survival results" Will there be clinical implications in the future?. <i>European Journal of Radiology</i> , 2013, 82, 1591-1592.	2.6	1
53	Systemic Therapy, Radiotherapy, and Cardiotoxicity. , 2013, , 165-182.		1
54	Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?. <i>Archives of Gynecology and Obstetrics</i> , 2012, 285, 499-503.	1.7	0

#	ARTICLE	IF	CITATIONS
55	Gonadal agenesis with hypoplastic paramesonephric ducts (PMNDs) derivatives in dizygotic twins. Gynecological Endocrinology, 2016, 32, 792-795.	1.7	0
56	New Agents in the Treatment of Advanced Gastric Cancer: Targeted Therapy and Immunotherapy. Current Clinical Pathology, 2019, , 121-132.	0.0	0
57	Complete and Durable Response to Combined Chemo/Radiation Therapy in EGFR Wild-Type Lung Adenocarcinoma with Diffuse Brain Metastases. Diagnostics, 2019, 9, 42.	2.6	0
58	Evidence-Based Medicine: What does it Mean and Where Are We Going?. , 2010, , 221-241.		0